Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Authors:
- Beatriz Mateos-MuñozBMBeatriz Mateos-Muñoz
- María ButiMBMaría Buti
- Inmaculada Fernández VázquezIVInmaculada Fernández Vázquez
- Marta Hernández CondeMCMarta Hernández Conde
- Vanesa Bernal-MonterdeVBVanesa Bernal-Monterde
- Fernando Díaz-FontenlaFDFernando Díaz-Fontenla
- Rosa María MorillasRMRosa María Morillas
- Luisa García-BueyLGLuisa García-Buey
- Ester BadíaEBEster Badía
- Mireia MiquelMMMireia Miquel
- Alberto Amador-NavarreteAAAlberto Amador-Navarrete
- Sergio Rodríguez-TajesSRSergio Rodríguez-Tajes
Open Access
- 3 February 2023
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (6) , 2731-2737
Abstract
Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). Conclusion Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.Keywords
Funding Information
- Universidad de Alcalá
This publication has 21 references indexed in Scilit:
- Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral TherapyAnnals of Internal Medicine, 2020
- Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapyJournal of Viral Hepatitis, 2020
- Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infectionHepatology Research, 2020
- A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19Antiviral Research, 2020
- Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infectionJournal of Viral Hepatitis, 2020
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking studyLife Sciences, 2020
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Evaluation of the Propensity score methods for estimating marginal odds ratios in case of small sample sizeBMC Medical Research Methodology, 2012
- Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary CellsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*Antimicrobial Agents and Chemotherapy, 2002